Functional ovarian hyperandrogenism and polycystic ovary syndrome in prepubertal girls with obesity and/or premature pubarche

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue 4, 2007, Pages 475-481

  Şiklar, Zeynep ^a,b   Öçal, Gönül ^a   Adiyaman, Pelin ^a   Ergur, Ayça ^a   Berberoǧlu, Merih ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Dyslipidemia; Obesity; Polycystic ovary syndrome; Premature pubarche; Prepubertal girls

Indexed keywords

ANDROGEN; CHOLESTEROL; CORTICOTROPIN; FOLLITROPIN; GLUCOSE; GONADORELIN DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROGESTERONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BLOOD SAMPLING; BODY MASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN TEST; DIET RESTRICTION; DIET THERAPY; ECHOGRAPHY; ENVIRONMENTAL FACTOR; EXERCISE; FEMALE; GENETIC POLYMORPHISM; HUMAN; HYPERANDROGENISM; IMMUNORADIOMETRIC ASSAY; INSULIN RESISTANCE; OBESITY; OVARY POLYCYSTIC DISEASE; PRECOCIOUS PUBERTY; PREPUBERTY; RISK FACTOR;

EID: 34249869005     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2007.20.4.475     Document Type: Article

References (24)

1. Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B, Herrmann BL, Knebel B, Müller-Wieland D, Mann K, Janssen OE. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol 2005; 62: 573-579.
2. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34: 677-705.
3. Cussons AJ, Stuckey BGA, Walsh JP, Burke V, Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists in diagnosis and management. Clin Endocrinol 2005; 62: 289-295.
4. Arslanian S, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. Endocrinol Metab 2001; 86: 66-71.
5. Ibanez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogwnism. J Clin Endocrinol Metab 2003; 88: 2600-2606.
6. Ibanez L, de Zegher F, Potau N. Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. J Endocrinol Invest 1998; 21: 558-566.
7. Rosenfield RL. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol 2001; 45: 95-104.
8. Ibanez L, Ferrer A, Marcos MV. Hyperandrogenism and excess weight gain. J Pediatr Endocrinol Metab 2005; 18: 1199-1205.
9. Ibanez L, Valls C, Marcos MV, Ong K, Dunger DB, de Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal discontinuation of metformin treatment. J Clin Endocrinol Metab 2004; 89: 4331-4337.
10. Ibanez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinye M, Carrascosa A, Vicens-Calvet E. Post-pubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76: 1599-1603.
11. Rao JK, Chihal HS, Johnson CM. Primary polycystic ovary syndrome in a premenarchal girl. A case report. J Reprod Med 1985; 30: 361-365.
12. Silfen ME, Shackleton CHL, Manibo AM, Levine LS, Sekhar D, McMahon DJ, Oberfield SE. 5α-Reductase and 11β-hydroxysteroid dehydrogenase activity in pre-pubertal Hispanic girls with premature adrenarche. J Clin Endocrinol Metab 2002; 87: 4647-4651.
13. Bundak R, Furman A, Gunoz H, Darendeliler F, Bas F, Neyzi O. Body mass index references for Turkish children. Acta Paediatr 2006; 95: 194-198.
14. Cutfield WS, Hofman PL. Simple fasting methods to assess insulin sensitivity in childhood. Horm Res 2005; 64 (Suppl 3): 25-31.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-419.
16. Tresaco B, Bueno G, Pineda I, Moreno LA, Garagorri JM, Bueno M. Homeostatic model assessment (HOMA) index cut-off values to identify the metabolic syndrome in children. J Physiol Biochem 2005; 61: 381-388.
17. Şahin Y, Keleştimur F. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome. Clin Endocrinol 1993; 39: 151-155.
18. Rosenfield RL, Barnes B, Ehrmann A. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1994; 79: 1686-1692.
19. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauher ES, Yildiz B. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749.
20. Legro RS. Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2002; 15: 1367-1378.
21. Cetinkaya E, Ocal G, Berberoglu M, Adiyaman P. The risk of functional ovarian hyperandrogenism and polycystic ovary syndrome in patients with hyperandrogenism. J Pediatr Endocrinol Metab 2003; 16: 1011-1016.
22. Guzick D. Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. Am J Obst Gynecol 1998; 179: 89-93.
23. Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin 2001; 28: 99-109.
24. Ibanez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004; 144: 23-29.